NASDAQ:CARA Cara Therapeutics (CARA) Stock Price, News & Analysis $0.37 +0.01 (+2.76%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.37▼$0.3950-Day Range$0.24▼$0.7752-Week Range$0.24▼$3.45Volume513,613 shsAverage Volume1.27 million shsMarket Capitalization$20.36 millionP/E RatioN/ADividend YieldN/APrice Target$3.93 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cara Therapeutics alerts: Email Address Cara Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside956.2% Upside$3.93 Price TargetShort InterestHealthy1.35% of Float Sold ShortDividend StrengthN/ASustainability-1.39Upright™ Environmental ScoreNews Sentiment0.42Based on 3 Articles This WeekInsider TradingSelling Shares$2,952 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.28) to ($0.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.76 out of 5 starsMedical Sector46th out of 930 stocksPharmaceutical Preparations Industry15th out of 436 stocks 4.0 Analyst's Opinion Consensus RatingCara Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageCara Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cara Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.35% of the float of Cara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCara Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cara Therapeutics has recently decreased by 68.22%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCara Therapeutics does not currently pay a dividend.Dividend GrowthCara Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCara Therapeutics has received a 61.20% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for physical health" and "Opioid painkillers" products. See details.Environmental SustainabilityThe Environmental Impact score for Cara Therapeutics is -1.39. Previous Next 2.5 News and Social Media Coverage News SentimentCara Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cara Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for CARA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows14 people have added Cara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,952.00 in company stock.Percentage Held by InsidersOnly 3.10% of the stock of Cara Therapeutics is held by insiders.Percentage Held by Institutions44.66% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cara Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Cara Therapeutics are expected to grow in the coming year, from ($1.28) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cara Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cara Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCara Therapeutics has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cara Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…All you have to do is claim your free ticket to the event now… About Cara Therapeutics Stock (NASDAQ:CARA)Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Read More CARA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CARA Stock News HeadlinesJuly 24, 2024 | americanbankingnews.comCara Therapeutics (NASDAQ:CARA) Research Coverage Started at StockNews.comJuly 21, 2024 | msn.comNow a Decade Into Her Career, Alessia Cara Says Things Feel 'Brand New Again' (Exclusive)July 28, 2024 | Crypto 101 Media (Ad)“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…June 13, 2024 | benzinga.comThese Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'June 13, 2024 | investorplace.comWhy Is Cara Therapeutics (CARA) Stock Down 27% Today?June 12, 2024 | reuters.comCara Therapeutics discontinues study on a neurological condition as drug failsJune 12, 2024 | globenewswire.comCara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia ParestheticaMay 29, 2024 | yahoo.comLaurel's Plan to Take Out Cara Maria Leads to a Stunning Blindside on 'The Challenge: All Stars' Season 4July 28, 2024 | Crypto 101 Media (Ad)“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…May 29, 2024 | yahoo.comWhy Laurel Stucky Is Coming for Cara Maria on The ChallengeMay 29, 2024 | msn.com5 Reasons Why Cara Delevingne Is Us Weekly’s Woman CrushMay 14, 2024 | finanznachrichten.deCara Therapeutics, Inc.: Cara Therapeutics Reports First Quarter 2024 Financial ResultsMay 14, 2024 | markets.businessinsider.comIn-Depth Examination Of 5 Analyst Recommendations For Cara TherapeuticsMay 13, 2024 | investorplace.comCARA Stock Earnings: Cara Therapeutics Misses EPS, Beats Revenue for Q1 2024May 13, 2024 | chron.comCara: Q1 Earnings SnapshotMay 13, 2024 | globenewswire.comCara Therapeutics Reports First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comCara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024May 2, 2024 | yahoo.comCara Maria Hatches a Revenge Plot on 'The Challenge: All Stars' Season 4See More Headlines Receive CARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/28/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CARA CUSIPN/A CIK1346830 Webwww.caratherapeutics.com Phone(203) 406-3700Fax203-567-1510Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$3.93 High Stock Price Target$12.00 Low Stock Price Target$1.00 Potential Upside/Downside+956.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,510,000.00 Net Margins-723.49% Pretax Margin-723.49% Return on Equity-174.15% Return on Assets-105.26% Debt Debt-to-Equity RatioN/A Current Ratio5.38 Quick Ratio5.20 Sales & Book Value Annual Sales$20.97 million Price / Sales0.97 Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book0.35Miscellaneous Outstanding Shares54,680,000Free Float52,981,000Market Cap$20.36 million OptionableOptionable Beta0.69 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Christopher A. Posner (Age 54)President, CEO & Director Comp: $1.2MMr. Ryan D. Maynard (Age 55)Chief Financial Officer Comp: $511.7kDr. Joana Goncalves M.D. (Age 50)Chief Medical Officer Comp: $747.25kDr. Derek T. Chalmers D.Sc. (Age 60)Ph.D., Co-Founder & Senior Advisor Comp: $580.93kDr. Iris Francesconi Ph.D.Chief Strategy Officer & Head of Investor RelationsMr. Scott M. Terrillion (Age 61)Chief Compliance Officer, General Counsel & Corporate Secretary Comp: $689.63kMs. Beth Weinberg R.Ph.Senior Vice President of Regulatory Affairs & QAMr. Matthew MurphyManager of Investor RelationsMore ExecutivesKey CompetitorsInstil BioNASDAQ:TILEstrella ImmunopharmaNASDAQ:ESLAChimerixNASDAQ:CMRXSCYNEXISNASDAQ:SCYXKronos BioNASDAQ:KRONView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 149,809 shares on 5/10/2024Ownership: 4.539%Acadian Asset Management LLCSold 26,242 shares on 5/10/2024Ownership: 0.611%Marquette Asset Management LLCBought 94,238 shares on 5/7/2024Ownership: 0.172%Christopher PosnerSold 3,936 sharesTotal: $2,952.00 ($0.75/share)Joana GoncalvesSold 2,753 sharesTotal: $2,284.99 ($0.83/share)View All Insider TransactionsView All Institutional Transactions CARA Stock Analysis - Frequently Asked Questions How have CARA shares performed this year? Cara Therapeutics' stock was trading at $0.7430 at the start of the year. Since then, CARA stock has decreased by 49.9% and is now trading at $0.3724. View the best growth stocks for 2024 here. How were Cara Therapeutics' earnings last quarter? Cara Therapeutics, Inc. (NASDAQ:CARA) released its earnings results on Monday, May, 13th. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.18. The biopharmaceutical company had revenue of $2.14 million for the quarter, compared to analyst estimates of $2.25 million. Cara Therapeutics had a negative trailing twelve-month return on equity of 174.15% and a negative net margin of 723.49%. How do I buy shares of Cara Therapeutics? Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX). This page (NASDAQ:CARA) was last updated on 7/28/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredOwn NVDA? Prepare for a “cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.